PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2148337
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2148337
Gene Manufacturing Market is estimated to be valued at USD 9.18 Bn in 2026 and is expected to reach USD 26.25 Bn by 2033, growing at a compound annual growth rate (CAGR) of 16.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 9.18 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 16.20% | 2033 Value Projection: | USD 26.25 Bn |
The global gene manufacturing market is a disruptive sector of the biotechnology and life sciences industry that encompasses the mass production of plasmid DNA, viral vectors, mRNA and other nucleic acid-based products. The manufacturing capabilities underpin the development of gene therapy, cell therapy, CAR-T treatments and next-generation vaccines, which in turn fuels demand for scalable, high-quality and regulatory compliant production systems.
The global gene manufacturing market is driven by increasing investments in gene-based therapeutic pipelines for rare genetic conditions, cancer, and infectious diseases, which in turn increases the demand for advanced manufacturing infrastructure. It brings together biopharmaceutical companies, CDMOs, academic institutions, and government agencies, with continuous advances in genomics and bioprocessing further strengthening the demand for efficient and commercially scalable gene manufacturing technologies.
The global gene manufacturing market is driven by the rising number of gene and cell therapies progressing through clinical and commercial development and the growing need for scalable manufacturing capacity. The growth of mRNA-based technologies, government funding, public-private partnerships and collaborations in the industry are also driving investment in advanced manufacturing infrastructure.
However, a number of constraints are present in the market, such as high capital expenditure for cGMP facilities, complexity of viral-vector production, yield and batch consistency challenges and evolving regulatory requirements. Nevertheless, significant opportunities exist within the increasing outsourcing of gene manufacturing to specialized CDMOs, especially for small biopharmaceutical companies looking for flexible and cost-efficient production capabilities. Manufacturing efficiency and scalability are being improved by bioprocess automation, single-use systems, and AI-enabled quality control, while expanding gene-therapy pipelines targeting neurological, cardiovascular, and inherited metabolic disorders are driving further demand for specialized manufacturing capacity.